Reni BenjaminManaging Director and Senior Biotechnology Analyst at Raymond James
Dr. Reni John Benjamin, also known as Ren, Ph.D. is a Senior Biotechnology Analyst at Raymond James & Associates, Inc., Research Division. His expertise focuses on companies in the oncology and stem cell within biotechnology sectors at the firm. Previously, Dr. Benjamin was a Biotechnology Analyst at the firm. He served as Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co, LLC, Research Division from September 2013 to June 2015 and covered the biotechnology sector. Dr. Benjamin worked at Burrill & Company, Research Division where he served as Managing Director and Senior Equity Research Analyst since August 1, 2012. Dr. Benjamin served as Managing Director and Senior Biotechnology Analyst at Rodman & Renshaw Research from 2003 to June 30, 2012. Prior to that, he was an Associate Analyst in the biotechnology equity research department at Needham & Company, LLC, Research Division. Dr. Benjamin is a past member of the UAB School of Health Professions' Deans Advisory Board. He has expertise in small- and mid-cap companies in the oncology and stem cell sectors and has previously been ranked among the top analyst by StarMine for recommendation performance and earnings estimate accuracy. Dr. Benjamin has been cited in a variety of sources including The Wall Street Journal, Bloomberg Businessweek, Financial Times and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He authored a chapter in "The Delivery of Regenerative Medicines and Their Impact on Healthcare," has presented at various regional and international conferences, and has been published in peer-reviewed journals. Dr. Benjamin earned a Ph.D. in Biochemistry and Molecular Genetics by discovering and characterizing a novel gene implicated in germ cell development at the University of Alabama at Birmingham and a B.S. in Biology from Allegheny College.